立体定向消融放疗治疗原发性头颈癌及局部区域复发:文献综合综述
本综述系统检索并批判性评估了立体定向消融放疗(SABR)用于头颈癌原发治疗及既往照射野内局部区域复发的文献。原发情况下,SABR作为根治性放疗后推量或局限于小范围声门癌的单一模式治疗似乎有前景;复发情况下SABR可为有用手段,但靠近既往照射的颈动脉或其他串联危及器官时需谨慎。通常仅治疗有限大体肿瘤体积,每两天一次共3-6次,累积剂量24-44 Gy。
要点
- 原发头颈癌SABR前瞻性数据很少,作为根治性放疗后推量或小范围声门癌单一治疗似乎有前景
- SABR可用于既往照射野内局部复发,但靠近既往照射的颈动脉或其他串联危及器官时需谨慎
- 通常仅治疗有限大体肿瘤体积,每两天一次共3-6次,累积剂量24-44 Gy
核心结论
- SABR是一种创新、有效且有前景的治疗方式,适用于小靶区,尤其靠近危及器官或位于既往照射区域时。
- 需要进一步开展前瞻性试验,该技术才能成为标准治疗。
研究设计与样本
- 本文为文献综合综述,对SABR作为原发治疗及治疗既往照射野内局部区域复发疾病的相关文献进行了全面检索和批判性评估。
主要发现
- 迄今关于SABR治疗头颈癌的前瞻性数据发表很少。
- 原发情况下,SABR作为根治性放疗后推量或作为局限于小范围声门癌的单一模式治疗似乎有前景。
- SABR可作为治疗既往照射野内局部复发的有用手段。
- 靠近既往照射的颈动脉或其他串联危及器官时需谨慎。
- 通常仅治疗有限大体肿瘤体积,每两天一次共3-6次,累积剂量24-44 Gy,使用专用放射外科平台或具备在线影像引导和充分固定的现代直线加速器。
关键数值与推荐
- 通常仅治疗有限大体肿瘤体积,每两天一次共3-6次,累积剂量24-44 Gy。
- 治疗在专用放射外科平台或具备在线影像引导和充分固定的现代直线加速器上进行。
临床怎么用
- 原文未据此给出推荐。
局限性
- 迄今关于SABR治疗头颈癌的前瞻性数据发表很少。
- 需要进一步开展前瞻性试验,该技术才能成为标准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Although stereotactic ablative radiotherapy (SABR) has advance to standard-of-care for many different indications like lung and liver malignancies, it still remains in its infancy for treating head and neck cancer. Nevertheless there is a growing body of experience and evidence, which is summarized in this review Methods A thorough search of the literature was performed and critically reviewed both for SABR as a primary treatment as well as for treating locoregionally recurrent disease in a pre-irradiated field. RESULTS: There exist only few prospective data published so far for treating head and neck cancer with SABR. In the primary situation especially implementing SABR as a boost after definitive radiotherapy or a single-modality for locally limited, small glottic cancer appear promising. On the other hand, SABR can be a useful modality for treating local recurrence in a pre-irradiated field. However, caution is needed in the case of proximity to a pre-irradiated carotid artery or other serial organs at risk. Usually only limited gross volumes are treated with 3-6 fractions every other day and a cumulative dose of 24-44 Gy in dedicated radiosurgery platforms or modern linacs with the possibility of online image-guidance and adequate immobilsation. CONCLUSIONS: SABR is an innovative, effective and promising treatment modality for small targets, especially in near proximity to organs at risk or in a pre-irradiated region. Prospective trials are further needed for this technique to become standard-of care.
引用
- Franzese C, Balermpas P. Stereotactic ablative radiotherapy for treating primary head and neck cancer and locoregional recurrence: A comprehensive review of the literature. Clin Transl Radiat Oncol. 2024. PMID: 38590327. doi:10.1016/j.ctro.2024.100766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。